Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial

A nested case-control study

Song Yao, Cathee Till, Alan R. Kristal, Phyllis J. Goodman, Ann W. Hsing, Catherine M. Tangen, Elizabeth A. Platz, Frank Z. Stanczyk, Juergen K V Reichardt, Li Tang, Marian L. Neuhouser, Regina M. Santella, William D. Figg, Douglas K. Price, Howard L. Parnes, Scott M. Lippman, Ian M. Thompson, Christine B. Ambrosone, Ashraful Hoque

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: Finasteride reduces prostate cancer risk by blocking the conversion of testosterone to dihydrotestosterone. However, whether finasteride affects estrogens levels or change in estrogens affects prostate cancer risk is unknown.Methods These questions were investigated in a case- control study nested within the prostate cancer prevention trial (PCPT) with 1,798 biopsy-proven prostate cancer cases and 1,798 matched controls. Results: Among men on placebo, no relationship of serum estrogens with risk of prostate cancer was found. Among those on finasteride, those in the highest quartile of baseline estrogen levels had a moderately increased risk of Gleason score\7 prostate cancer (for estrone, odds ratio [OR] = 1.51, 95% confidence interval [CI] = 1.06-2.15; for estradiol, OR = 1.50, 95% CI = 1.03-2.18). Finasteride treatment increased serum estrogen concentrations; however, these changes were not associated with prostate cancer risk. Conclusion Our findings confirm those from previous studies that there are no associations of serum estrogen with prostate cancer risk in untreated men. In addition, finasteride results in a modest increase in serum estrogen levels, which are not related to prostate cancer risk. Whether finasteride is less effective in men with high serum estrogens, or finasteride interacts with estrogen to increase cancer risk, is uncertain and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)1121-1131
Number of pages11
JournalCancer Causes and Control
Volume22
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Finasteride
Case-Control Studies
Prostatic Neoplasms
Estrogens
Serum
Odds Ratio
Confidence Intervals
Neoplasm Grading
Estrone
Dihydrotestosterone
Testosterone
Estradiol
Placebos
Biopsy

Keywords

  • Estradiol
  • Estrogen
  • Etiology
  • Nested case-control study
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yao, S., Till, C., Kristal, A. R., Goodman, P. J., Hsing, A. W., Tangen, C. M., ... Hoque, A. (2011). Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: A nested case-control study. Cancer Causes and Control, 22(8), 1121-1131. https://doi.org/10.1007/s10552-011-9787-7

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial : A nested case-control study. / Yao, Song; Till, Cathee; Kristal, Alan R.; Goodman, Phyllis J.; Hsing, Ann W.; Tangen, Catherine M.; Platz, Elizabeth A.; Stanczyk, Frank Z.; Reichardt, Juergen K V; Tang, Li; Neuhouser, Marian L.; Santella, Regina M.; Figg, William D.; Price, Douglas K.; Parnes, Howard L.; Lippman, Scott M.; Thompson, Ian M.; Ambrosone, Christine B.; Hoque, Ashraful.

In: Cancer Causes and Control, Vol. 22, No. 8, 08.2011, p. 1121-1131.

Research output: Contribution to journalArticle

Yao, S, Till, C, Kristal, AR, Goodman, PJ, Hsing, AW, Tangen, CM, Platz, EA, Stanczyk, FZ, Reichardt, JKV, Tang, L, Neuhouser, ML, Santella, RM, Figg, WD, Price, DK, Parnes, HL, Lippman, SM, Thompson, IM, Ambrosone, CB & Hoque, A 2011, 'Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: A nested case-control study', Cancer Causes and Control, vol. 22, no. 8, pp. 1121-1131. https://doi.org/10.1007/s10552-011-9787-7
Yao, Song ; Till, Cathee ; Kristal, Alan R. ; Goodman, Phyllis J. ; Hsing, Ann W. ; Tangen, Catherine M. ; Platz, Elizabeth A. ; Stanczyk, Frank Z. ; Reichardt, Juergen K V ; Tang, Li ; Neuhouser, Marian L. ; Santella, Regina M. ; Figg, William D. ; Price, Douglas K. ; Parnes, Howard L. ; Lippman, Scott M. ; Thompson, Ian M. ; Ambrosone, Christine B. ; Hoque, Ashraful. / Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial : A nested case-control study. In: Cancer Causes and Control. 2011 ; Vol. 22, No. 8. pp. 1121-1131.
@article{0faac62db7b5440faa90356a935fa6bc,
title = "Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: A nested case-control study",
abstract = "Objective: Finasteride reduces prostate cancer risk by blocking the conversion of testosterone to dihydrotestosterone. However, whether finasteride affects estrogens levels or change in estrogens affects prostate cancer risk is unknown.Methods These questions were investigated in a case- control study nested within the prostate cancer prevention trial (PCPT) with 1,798 biopsy-proven prostate cancer cases and 1,798 matched controls. Results: Among men on placebo, no relationship of serum estrogens with risk of prostate cancer was found. Among those on finasteride, those in the highest quartile of baseline estrogen levels had a moderately increased risk of Gleason score\7 prostate cancer (for estrone, odds ratio [OR] = 1.51, 95{\%} confidence interval [CI] = 1.06-2.15; for estradiol, OR = 1.50, 95{\%} CI = 1.03-2.18). Finasteride treatment increased serum estrogen concentrations; however, these changes were not associated with prostate cancer risk. Conclusion Our findings confirm those from previous studies that there are no associations of serum estrogen with prostate cancer risk in untreated men. In addition, finasteride results in a modest increase in serum estrogen levels, which are not related to prostate cancer risk. Whether finasteride is less effective in men with high serum estrogens, or finasteride interacts with estrogen to increase cancer risk, is uncertain and warrants further investigation.",
keywords = "Estradiol, Estrogen, Etiology, Nested case-control study, Prostate cancer",
author = "Song Yao and Cathee Till and Kristal, {Alan R.} and Goodman, {Phyllis J.} and Hsing, {Ann W.} and Tangen, {Catherine M.} and Platz, {Elizabeth A.} and Stanczyk, {Frank Z.} and Reichardt, {Juergen K V} and Li Tang and Neuhouser, {Marian L.} and Santella, {Regina M.} and Figg, {William D.} and Price, {Douglas K.} and Parnes, {Howard L.} and Lippman, {Scott M.} and Thompson, {Ian M.} and Ambrosone, {Christine B.} and Ashraful Hoque",
year = "2011",
month = "8",
doi = "10.1007/s10552-011-9787-7",
language = "English (US)",
volume = "22",
pages = "1121--1131",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "8",

}

TY - JOUR

T1 - Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial

T2 - A nested case-control study

AU - Yao, Song

AU - Till, Cathee

AU - Kristal, Alan R.

AU - Goodman, Phyllis J.

AU - Hsing, Ann W.

AU - Tangen, Catherine M.

AU - Platz, Elizabeth A.

AU - Stanczyk, Frank Z.

AU - Reichardt, Juergen K V

AU - Tang, Li

AU - Neuhouser, Marian L.

AU - Santella, Regina M.

AU - Figg, William D.

AU - Price, Douglas K.

AU - Parnes, Howard L.

AU - Lippman, Scott M.

AU - Thompson, Ian M.

AU - Ambrosone, Christine B.

AU - Hoque, Ashraful

PY - 2011/8

Y1 - 2011/8

N2 - Objective: Finasteride reduces prostate cancer risk by blocking the conversion of testosterone to dihydrotestosterone. However, whether finasteride affects estrogens levels or change in estrogens affects prostate cancer risk is unknown.Methods These questions were investigated in a case- control study nested within the prostate cancer prevention trial (PCPT) with 1,798 biopsy-proven prostate cancer cases and 1,798 matched controls. Results: Among men on placebo, no relationship of serum estrogens with risk of prostate cancer was found. Among those on finasteride, those in the highest quartile of baseline estrogen levels had a moderately increased risk of Gleason score\7 prostate cancer (for estrone, odds ratio [OR] = 1.51, 95% confidence interval [CI] = 1.06-2.15; for estradiol, OR = 1.50, 95% CI = 1.03-2.18). Finasteride treatment increased serum estrogen concentrations; however, these changes were not associated with prostate cancer risk. Conclusion Our findings confirm those from previous studies that there are no associations of serum estrogen with prostate cancer risk in untreated men. In addition, finasteride results in a modest increase in serum estrogen levels, which are not related to prostate cancer risk. Whether finasteride is less effective in men with high serum estrogens, or finasteride interacts with estrogen to increase cancer risk, is uncertain and warrants further investigation.

AB - Objective: Finasteride reduces prostate cancer risk by blocking the conversion of testosterone to dihydrotestosterone. However, whether finasteride affects estrogens levels or change in estrogens affects prostate cancer risk is unknown.Methods These questions were investigated in a case- control study nested within the prostate cancer prevention trial (PCPT) with 1,798 biopsy-proven prostate cancer cases and 1,798 matched controls. Results: Among men on placebo, no relationship of serum estrogens with risk of prostate cancer was found. Among those on finasteride, those in the highest quartile of baseline estrogen levels had a moderately increased risk of Gleason score\7 prostate cancer (for estrone, odds ratio [OR] = 1.51, 95% confidence interval [CI] = 1.06-2.15; for estradiol, OR = 1.50, 95% CI = 1.03-2.18). Finasteride treatment increased serum estrogen concentrations; however, these changes were not associated with prostate cancer risk. Conclusion Our findings confirm those from previous studies that there are no associations of serum estrogen with prostate cancer risk in untreated men. In addition, finasteride results in a modest increase in serum estrogen levels, which are not related to prostate cancer risk. Whether finasteride is less effective in men with high serum estrogens, or finasteride interacts with estrogen to increase cancer risk, is uncertain and warrants further investigation.

KW - Estradiol

KW - Estrogen

KW - Etiology

KW - Nested case-control study

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=82955213041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955213041&partnerID=8YFLogxK

U2 - 10.1007/s10552-011-9787-7

DO - 10.1007/s10552-011-9787-7

M3 - Article

VL - 22

SP - 1121

EP - 1131

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 8

ER -